Inclusion Criteria:

1. Histologically or cytologically proven non small cell lung cancer

2. New developed or progression of brain lesions among patients with good control of
extracranial lesions to erlotinib

3. patients who are receiving erlotinib as salvage therapy

4. At least one unidimensionally measurable lesion with a diameter > 10mm using brain
MRI

5. at least on unidimensionally measurable or evaluable lesion

6. male or female patients aged >18 years

7. ECOG performance status 0-2

8. Adequate hematologic function

9. adequate renal function

10. adequate hepatic function

Exclusion criteria

1. leptomeningeal metastases

2. acute severe infection requiring antibiotic therapy

3. significant cardiovascular disease

4. uncontrolled DM

5. severe ophthalmologic disease